Navigation Links
Study Demonstrates a Safe and Cost Effective Source of Recombinant Human Transferrin
Date:6/17/2010

Optiferrin, InVitria’s recombinant human transferrin, outperforms iron chelators and provides a cost-effective cell culture media supplement that is consistent and animal component free.

Fort Collins, CO (PRWEB) June 17, 2010 -- A shift in the life science market has begun to steer cell culture scientists to re-evaluate their use of native transferrin and iron chelators to pursue recombinant alternatives. Transferrin regulates the uptake, transport and utilization of iron for cellular function, increasing cell growth and productivity. Native transferrin found in bovine or human serum has been widely used in cell culture for these added benefits. However, regulatory issues continue to arise with the use of native transferrin due to blood-borne pathogens.

A recent study published May 2010 in the Protein Expression and Purification Journal demonstrated that transferrin is efficiently produced using recombinant technology. The study, ‘Expression, Purification and Characterization of Recombinant Human Transferrin from Rice’ concluded that recombinant human transferrin can be expressed at very high levels of 10 grams per kilogram of biomass. These results were accomplished by utilizing the unique and proprietary expression system known as ExpressTec.

“Using the ExpressTec system for animal component free production of recombinant proteins has proven to not only provide safety and regulatory advantages, but also allows cost-effective sources of recombinant proteins like transferrin,” said Ning Huang, Vice President of Research and Development at InVitria.

Rice-derived recombinant human transferrin, tradename OptiferrinTM, is structurally and functionally similar to native transferrin. The results of this study show that effective and efficient methods of producing recombinant proteins enable products like Optiferrin to be cost effective and safe when compared to animal-derived transferrin.

“In this paper, we describe the unrivaled efficiency that we have achieved in a plant-based production system. These expression yields are significantly higher than other systems, which is critical to achieving commercially attractive products like Optiferrin, recombinant human transferrin,” said Deshui Zhang, InVitria Scientist and Lead Author.

InVitria has utilized Optiferrin to develop cell culture media supplements that avoid concerns about blood-borne pathogens found in animal or human serum while still optimizing performance in cell culture. Optiferrin eliminates the nuisances of serum contamination and iron chelators in mammalian cell culture by providing a well defined, high performance and animal-free solution.

“Transferrin delivers necessary iron to cells, maintains iron balance, and avoids the toxic effects of iron compounds. Optiferrin outperforms iron chelators and provides a cost effective alternative to animal-derived transferrin,” said Dr. Steve Pettit, Director of Cell Culture Research and Development at InVitria.

Optiferrin is suitable for all applications in mammalian cell culture, stem cells, regenerative medicine and biopharmaceutical drug delivery. To learn more about Optiferrin and to purchase online please visit www.Optiferrin.com.

About InVitria – InVitria.com
InVitria develops, manufactures and markets a portfolio of high performance and well defined cell culture media supplements and reagents used in bioprocessing, biopharmaceutical formulation, stem cell & regenerative medicine, life science research, medical devices and diagnostics.

For more information about InVitria’s products, please e-mail info(at)InVitria(dot)com.

All InVitria products can be purchased online at www.InVitria.com or by calling 1-800-916-8311.

###

Read the full story at http://www.prweb.com/releases/2010/06/prweb4155014.htm.


'/>"/>
Source: PRWeb
Copyright©2010 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Antiretrovirals During Breast-Feeding Shield Babies From HIV, Study Shows
2. Sex, drugs and moral goals: Penn study of reproductive strategies and recreational drug use
3. Twin study shows Mediterranean-style diet improves heart function
4. Study examines reasons patients with early stage lung cancer do not have surgery
5. UNC study helps explain why black patients with lung cancer have surgery less often than whites
6. Females May Be Naturally More Prone to Stress: Animal Study
7. Mastectomy Rates Down Overall, New Study Finds
8. Study: Getting patients to take their asthma meds
9. Study Probes Causes of Anger in Returning U.S. Soldiers
10. Study: Specific PTSD symptoms related to anger and aggressiveness among Iraq/Afghanistan veterans
11. Study: Adults take their physical activity on the road
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Study Demonstrates a Safe and Cost Effective Source of Recombinant Human Transferrin 
(Date:2/8/2016)... ... February 08, 2016 , ... Delta Dental of California and its ... cancer. , Gary D. Radine, who recently retired as president and CEO of Delta ... 2015 CEO of the Year , helped lead the effort to raise funds ...
(Date:2/8/2016)... ... February 08, 2016 , ... Eating ... a significant number of women and men with eating disorders report a history ... best predicts the development of an eating disorder. , At the 2016 ...
(Date:2/8/2016)... ... February 08, 2016 , ... GrassrootsHealth published data from ... type 2 diabetes in the GrassrootsHealth cohort with substantially higher vitamin D levels ... in public health,” states Carole Baggerly, Director of GrassrootsHealth, “the safety and ...
(Date:2/8/2016)... ... February 08, 2016 , ... Joshua Rosenthal, PhD, Chief Scientific ... can use newly released government data on populations and physicians to better calculate ... capture the value they create to succeed in new economic models for value ...
(Date:2/8/2016)... , ... February 08, 2016 , ... ... only four states in the U.S. require dental technicians to be certified or ... the dental industry, NADL created the “What’s In Your Mouth?” campaign to inform ...
Breaking Medicine News(10 mins):
(Date:2/8/2016)... , Feb. 8, 2016  Echo Therapeutics, ... device company focused on non-invasive continuous glucose ... today announced that it will host a ... 17, 2015 at 9:00 a.m. Eastern Time ... its corporate strategy, advancements in its CGM ...
(Date:2/8/2016)... , Feb. 8, 2016 ... the "Global Skin Protective Equipment Market 2016-2020" ... --> http://www.researchandmarkets.com/research/fqx6nz/global_skin ) has announced the addition ... 2016-2020" report to their offering. ... ) has announced the addition of the ...
(Date:2/8/2016)... , Feb. 8, 2016   HighPoint ... November Research Group (NRG),s pharmacovigilance technology services division.  ... consulting services and an Oracle Argus Specialized partner, ... to Life Sciences companies. --> ... expands HighPoint,s life sciences capabilities and provides a ...
Breaking Medicine Technology: